Agmatine Induces Nrf2 and Protects Against Corticosterone Effects in Hippocampal Neuronal Cell Line

Molecular Neurobiology

Volumn 51, Issue 3, 2015, Pages 1504-1519

  Freitas, Andiara E ^a,b   Egea, Javier ^a   Buendía, Izaskun ^a   Navarro, Elisa ^a   Rada, Patricia ^c   Cuadrado, Antonio ^c   Rodrigues, Ana Lúcia S ^b   López, Manuela G ^a  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Agmatine; Akt; Antioxidant; ERK; Hemoxygenase 1; HT22 cells; Monoamines; Neuroprotection; Nrf2

Indexed keywords

AGMATINE; CORTICOSTERONE; NFE2L2 PROTEIN, MOUSE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SEROTONIN 2A RECEPTOR; TRANSCRIPTION FACTOR NRF2;

ANIMAL; CELL LINE; DRUG EFFECTS; GENETICS; HIPPOCAMPUS; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; MOUSE; SIGNAL TRANSDUCTION;

AGMATINE; ANIMALS; CELL LINE; CORTICOSTERONE; HIPPOCAMPUS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MAP KINASE SIGNALING SYSTEM; MICE; NF-E2-RELATED FACTOR 2; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, SEROTONIN, 5-HT2A;

EID: 84939877433     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8827-1     Document Type: Article

References (75)

1. WHO (2008) The global burden of disease: 2004 update: World Health Organization
2. Jacob V, Chattopadhyay SK, Sipe TA, Thota AB, Byard GJ, Chapman DP, Community Preventive Services Task Force (2012) Economics of collaborative care for management of depressive disorders: a community guide systematic review. Am J Prev Med 42:539–549. doi:10.1016/j.amepre.2012.01.011
3. Balak N, Elmaci I (2007) Costs of disorders of the brain in Europe. Eur J Neurol 14:e9. doi:10.1111/j.1468-1331.2006.01570.x
4. Carroll CGC, Mendels J (1976) Neuroendocrine regulation in depression. I. Limbic system-adrenocortical dysfunction. Arch Gen Psychiatry 33:1039–1044. doi:10.1001/archpsyc.1976.01770090029002
5. Frodl T, O’Keane V (2013) How does the brain deal with cumulative stress? A review with focus on developmental stress, HPA axis function and hippocampal structure in humans. Neurobiol Dis 52:24–37. doi:10.1016/j.nbd.2012.03.012
6. Maric NP, Adzic M (2013) Pharmacological modulation of HPA axis in depression—new avenues for potential therapeutic benefits. Psychiatr Danub 25:299–305
7. Pariante CM, Lightman SL (2008) The HPA axis in major depression: classical theories and new developments. Trends Neurosci 31:464–468. doi:10.1016/j.tins.2008.06.006
8. Swaab DF, Bao AM, Lucassen PJ (2005) The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 4:141–194. doi:10.1016/j.arr.2005.03.003
9. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM (2011) Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry 35:722–7229. doi:10.1016/j.pnpbp.2010.04.011
10. Lee AL, Ogle WO, Sapolsky RM (2002) Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord 4:117–128. doi:10.1034/j.1399-5618.2002.01144.x
11. Leonard B, Maes M (2012) Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 36:764–785. doi:10.1016/j.neubiorev.2011.12.005
12. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M (2009) The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 24:27–53. doi:10.1007/s11011-008-9118-1
13. Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, Chen PC (2008) The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 1147:61–69. doi:10.1196/annals.1427.036
14. Lee SY, Lee SJ, Han C, Patkar AA, Masand PS, Pae CU (2013) Oxidative/nitrosative stress and antidepressants: Targets for novel antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 46:224–235. doi:10.1016/j.pnpbp.2012.09.008
15. Maes M, Fišar Z, Medina M, Scapagnini G, Nowak G, Berk M (2012) New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 20:127–150. doi:10.1007/s10787-011-0111-7
16. Martín-de-Saavedra MD, Budni J, Cunha MP, Gómez-Rangel V, Lorrio S, Del Barrio L, Lastres-Becker I, Parada E, Tordera RM, Rodrigues AL, Cuadrado A, López MG (2013) Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. Psychoneuroendocrinology 38:2010–2022. doi:10.1016/j.psyneuen.2013.03.020
17. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, Yamamoto M (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24:7130–7139. doi:10.1128/MCB.24.16.7130-7139.2004
18. Uruno A, Motohashi H (2011) The Keap1-Nrf2 system as an in vivo sensor for electrophiles. Nitric Oxide 25:153–160. doi:10.1016/j.niox.2011.02.007
19. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, Talalay P (2002) Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A 99:11908–11913. doi:10.1073/pnas.172398899
20. Niture SK, Kaspar JW, Shen J, Jaiswal AK (2010) Nrf2 signaling and cell survival. Toxicol Appl Pharmacol 244:37–42. doi:10.1016/j.taap.2009.06.009
21. Huang HC, Nguyen T, Pickett CB (2002) Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem 277:42769–42774. doi:10.1074/jbc.M206911200
22. Nguyen T, Yang CS, Pickett CB (2004) The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med 37:433–441. doi:10.1016/j.freeradbiomed.2004.04.033
23. Surh YJ (2003) Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3:768–780. doi:10.1038/nrc1189
24. Turpaev KT (2013) Keap1-Nrf2 signaling pathway: mechanisms of regulation and role in protection of cells against toxicity caused by xenobiotics and electrophiles. Biochemistry (Mosc) 78:111–126. doi:10.1134/S0006297913020016
25. Jaiswal AK (2004) Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med 36:1199–1207. doi:10.1016/j.freeradbiomed.2004.02.074
26. Reis DJ, Regunathan S (2000) Is agmatine a novel neurotransmitter in brain? Trends Pharmacol Sci 21:187–193. doi:10.1016/S0165-6147(00)01460-7
27. Piletz JE, Aricioglu F, Cheng JT, Fairbanks CA, Gilad VH, Haenisch B, Halaris A, Hong S, Lee JE, Li J, Liu P, Molderings GJ, Rodrigues AL, Satriano J, Seong GJ, Wilcox G, Wu N, Gilad GM (2013) Agmatine: clinical applications after 100 years in translation. Drug Discov Today 17–18:880–893. doi:10.1016/j.drudis.2013.05.017
28. Reis DJ, Regunathan S (1999) Agmatine: an endogenous ligand at imidazoline receptors is a novel neurotransmitter. Ann N Y Acad Sci 881:65–80. doi:10.1111/j.1749-6632.1999.tb09343.x
29. Goracke-Postle CJ, Overland AC, Riedl MS, Stone LS, Fairbanks CA (2007) Potassium- and capsaicin-induced release of agmatine from spinal nerve terminals. J Neurochem 102:1738–1748. doi:10.1111/j.1471-4159.2007.04647.x
30. Tabor CW, Tabor H (1984) Polyamines. Ann Rev Biochem 53:749–790. doi:10.1146/annurev.bi.53.070184.003533
31. Seo S, Liu P, Leitch B (2011) Spatial learning-induced accumulation of agmatine and glutamate at hippocampal CA1 synaptic terminals. Neuroscience 192:28–36. doi:10.1016/j.neuroscience.2011.07.007
32. Reis DJ, Regunathan S (1998) Agmatine: an endogenous ligand at imidazoline receptors may be a novel neurotransmitter in brain. J Auton Nerv Syst 72:80–85
33. Zomkowski AD, Hammes L, Lin J, Calixto JB, Santos AR, Rodrigues AL (2002) Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 13:387–391
34. Zomkowski ADE, Rosa AO, Lin J, Santos AR, Calixto JB, Rodrigues ALS (2004) Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Res 1023:253–263. doi:10.1016/j.brainres.2004.07.041
35. Zomkowski AD, Santos AR, Rodrigues AL (2005) Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci Lett 381:279–283. doi:10.1016/j.neulet.2005.02.026
36. Freitas AE, Bettio LE, Neis VB, Santos DB, Ribeiro CM, Rosa PB, Farina M, Rodrigues AL (2014) Agmatine abolishes restraint stress-induced depressive-like behavior and hippocampal antioxidant imbalance in mice. Prog Neuropsychopharmacol Biol Psychiatry 50:143–150. doi:10.1016/j.pnpbp.2013.12.012
37. Neis VB, Manosso LM, Moretti M, Freitas AE, Daufenbach J, Rodrigues AL (2014) Depressive-like behavior induced by tumor necrosis factor-α is abolished by agmatine administration. Behav Brain Res 261:336–344. doi:10.1016/j.bbr.2013.12.038
38. Shopsin B (2013) The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: a pilot study. Acta Neuropsych 25:113–118
39. Zhu MY, Wang WP, Bissette G (2006) Neuroprotective effects of agmatine against cell damage caused by glucocorticoids in cultured rat hippocampal neurons. Neuroscience 141:2019–2027. doi:10.1016/j.neuroscience.2006.05.011
40. Denizot F, Lang R (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89:271–277
41. Martin D, Rojo A, Salinas M, Diaz R, Gallardo G, Alam J, De Galarreta CM, Cuadrado A (2004) Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem 279:8919–8929. doi:10.1074/jbc.M309660200
42. Ha HC, Woster PM, Yager JD, Casero RA Jr (1997) The role of polyamine catabolism in polyamine analogue-induced programmed cell death. Proc Natl Acad Sci U S A 94:11557–11562
43. Anisman H, Kokkinidis L, Merali Z (2002) Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes. Brain Behav Immun 16:544–556. doi:10.1016/S0889-1591(02)00011-9
44. Lang UE, Borgwardt S (2013) Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem 31:761–777. doi:10.1159/000350094
45. Gold PW, Goodwin FK, Chrousos GP (1988) Clinical and biochemical manifestations of depression: relation to the neurobiology of stress II. N Engl J Med 319:413–420. doi:10.1056/NEJM19880818319070
46. Jiang XZ, Li YF, Zhang YZ, Chen HX, Li J, Wang NP (2008) 5-HT1A/1B receptors, alpha2-adrenoceptors and the post-receptor adenylate cyclase activation in the mice brain are involved in the antidepressant-like action of agmatine. Yao Xue Xue Bao 43:467–473
47. Parada E, Egea J, Buendia I, Negredo P, Cunha AC, Cardoso S, Soares MP, López MG (2013) The microglial α7-acetylcholine nicotinic receptor is a key element in promoting neuroprotection by inducing heme oxygenase-1 via nuclear factor erythroid-2-related factor 2. Antioxid Redox Signal 19:1135–1148. doi:10.1089/ars.2012.4671
48. Baird L, Dinkova-Kostova AT (2011) The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol 85:241–272. doi:10.1007/s00204-011-0674-5
49. Kugaya A, Sanacora G (2005) Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 10:808–819
50. Paul IA, Skolnick P (2003) Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 1003:250–272. doi:10.1196/annals.1300.016
51. Musazzi L, Treccani G, Mallei A, Popoli M (2013) The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors. Biol Psychiatry 73:1180–1188. doi:10.1016/j.biopsych.2012.11.009
52. Gilad GM, Salame K, Rabey JM, Gilad VH (1996) Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci 58:PL 41–PL 46
53. Feng Y, Piletz JE, Leblanc MH (2002) Agmatine suppresses nitric oxide production and attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res 52:606–611. doi:10.1203/00006450-200210000-00023
54. Mun CH, Lee WT, Park KA, Lee JE (2010) Regulation of endothelial nitric oxide synthase by agmatine after transient global cerebral ischemia in rat brain. Anat Cell Biol 43:230–240. doi:10.5115/acb.2010.43.3.230
55. Kim JH, Yenari MA, Giffard RG, Cho SW, Park KA, Lee JE (2004) Agmatine reduces infarct area in a mouse model of transient focal cerebral ischemia and protects cultured neurons from ischemia-like injury. Exp Neurol 189:122–130. doi:10.1016/j.expneurol.2004.05.029
56. Gilad GM, Gilad VH (2000) Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats. Neurosci Lett 296:97–100. doi:10.1016/S0304-3940(00)01625-6
57. Kotil K, Kuscuoglu U, Kirali M, Uzun H, Akçetin M, Bilge T (2006) Investigation of the dose-dependent neuroprotective effects of agmatine in experimental spinal cord injury: a prospective randomized and placebo-control trial. J Neurosurg Spine 4:392–399
58. Yu CG, Marcillo AE, Fairbanks CA, Wilcox GL, Yezierski RP (2000) Agmatine improves locomotor function and reduces tissue damage following spinal cord injury. Neuroreport 11:3203–3207
59. Gilad GM, Gilad VH, Finberg JP, Rabey JM (2005) Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity. Neurochem Res 30:713–719
60. Matheus FC, Aguiar AS Jr, Castro AA, Villarinho JG, Ferreira J, Figueiredo CP, Walz R, Santos AR, Tasca CI, Prediger RD (2012) Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Behav Brain Res 235:263–272. doi:10.1016/j.bbr.2012.08.017
61. Olmos G, DeGregorio-Rocasolano N, Paz Regalado M, Gasull T, Assumpció Boronat M, Trullas R, Villarroel A, Lerma J, García-Sevilla JÁ (1999) Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Br J Pharmacol 127:1317–1326. doi:10.1038/sj.bjp.0702679
62. Wang WP, Iyo AH, Miguel-Hidalgo J, Regunathan S, Zhu MY (2006) Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. Brain Res 1084:210–216. doi:10.1016/j.brainres.2006.02.024
63. Bergin DH, Liu P (2010) Agmatine protects against beta-amyloid25-35-induced memory impairments in the rat. Neuroscience 169:794–811. doi:10.1016/j.neuroscience.2010.05.004
64. Condello S, Currò M, Ferlazzo N, Caccamo D, Satriano J, Ientile R (2011) Agmatine effects on mitochondrial membrane potential and NF-κB activation protect against rotenone-induced cell damage in human neuronal-like SH-SY5Y cells. J Neurochem 116:67–75. doi:10.1111/j.1471-4159.2010.07085.x
65. Brossaud J, Roumes H, Moisan MP, Pallet V, Redonnet A, Corcuff JB (2013) Retinoids and glucocorticoids target common genes in hippocampal HT22 cells. J Neurochem 125:518–531. doi:10.1111/jnc.12192
66. Duncan RS, Chapman KD, Koulen P (2009) The neuroprotective properties of palmitoylethanolamine against oxidative stress in a neuronal cell line. Mol Neurodegener 4:50. doi:10.1186/1750-1326-4-50
67. Fukui M, Choi HJ, Zhu BT (2010) Mechanism for the protective effect of resveratrol against oxidative stress-induced neuronal death. Free Radic Biol Med 49:800–813. doi:10.1016/j.freeradbiomed.2010.06.002
68. Mendelev N, Mehta SL, Idris H, Kumari S, Li PA (2012) Selenite stimulates mitochondrial biogenesis signaling and enhances mitochondrial functional performance in murine hippocampal neuronal cells. PLoS One 10:e47910. doi:10.1371/journal.pone.0047910
69. Li YF, Liu YQ, Huang WC, Luo ZP (2003) Cytoprotective effect is one of common action pathways for antidepressants. Acta Pharmacol Sin 24:996–1000
70. Wang H, Zhou X, Huang J, Mu N, Guo Z, Wen Q, Wang R, Chen S, Feng ZP, Zheng W (2013) The role of Akt/FoxO3a in the protective effect of venlafaxine against corticosterone-induced cell death in PC12 cells. Psychopharmacology (Berl) 228:129–141. doi:10.1007/s00213-013-3017-9
71. Krass M, Wegener G, Vasar E, Volke V (2008) Antidepressant-like effect of agmatine is not mediated by serotonin. Behav Brain Res 188:324–328. doi:10.1016/j.bbr.2007.11.013
72. Taksande BG, Kotagale NR, Tripathi SJ, Ugale RR, Chopde CT (2009) Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine. Neuropharmacology 57:415–424. doi:10.1016/j.neuropharm.2009.06.035
73. Drzyzga ŁR, Marcinowska A, Obuchowicz E (2009) Antiapoptotic and neurotrophic effects of antidepressants: a review of clinical and experimental studies. Brain Res Bull 79:248–257. doi:10.1016/j.brainresbull.2009.03.009
74. Young LT (2002) Neuroprotective effects of antidepressant and mood stabilizing drugs. J Psychiatry Neurosci 27:8–9
75. Lin HY, Yeh WL, Huang BR, Lin C, Lai CH, Lin H, Lu DY (2012) Desipramine protects neuronal cell death and induces heme oxygenase-1 expression in Mes23.5 dopaminergic neurons. PLoS One 11:e50138